- Home
- Publications
- Publication Search
- Publication Details
Title
Empagliflozin for the treatment of type 2 diabetes
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 15, Issue 16, Pages 2429-2441
Publisher
Informa Healthcare
Online
2014-10-10
DOI
10.1517/14656566.2014.966078
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
- (2014) Bernard Zinman et al. Cardiovascular Diabetology
- The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
- (2014) David ZI Cherney et al. Cardiovascular Diabetology
- Effect of Gemfibrozil, Rifampicin, or Probenecid on the Pharmacokinetics of the SGLT2 Inhibitor Empagliflozin in Healthy Volunteers
- (2014) Sreeraj Macha et al. CLINICAL THERAPEUTICS
- Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies
- (2014) Paul Nyirjesy et al. CURRENT MEDICAL RESEARCH AND OPINION
- Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
- (2014) Hans-Ulrich Häring et al. DIABETES CARE
- Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes
- (2014) Julio Rosenstock et al. DIABETES CARE
- SGLT2 inhibitors in the treatment of type 2 diabetes
- (2014) Farhad M. Hasan et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis
- (2014) William L. Baker et al. Journal of the American Society of Hypertension
- Urinary Tract Infection in Randomized Phase III Studies of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor
- (2014) Lindsay E. Nicolle et al. POSTGRADUATE MEDICINE
- Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
- (2014) Martin Ridderstråle et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
- (2014) Anthony H Barnett et al. Lancet Diabetes & Endocrinology
- Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations
- (2013) Wendy L. Bennett et al. ANNALS OF INTERNAL MEDICINE
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetics of Empagliflozin and Linagliptin After Coadministration in Healthy Male Volunteers
- (2013) Christian Friedrich et al. CLINICAL THERAPEUTICS
- Lack of Clinically Relevant Drug–Drug Interaction Between Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, and Verapamil, Ramipril, or Digoxin in Healthy Volunteers
- (2013) Sreeraj Macha et al. CLINICAL THERAPEUTICS
- Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes
- (2013) E. Ferrannini et al. DIABETES CARE
- Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial
- (2013) H.-U. Haring et al. DIABETES CARE
- Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment
- (2013) S. Macha et al. DIABETES OBESITY & METABOLISM
- Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment
- (2013) S. Macha et al. DIABETES OBESITY & METABOLISM
- Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes
- (2013) T. Heise et al. DIABETES OBESITY & METABOLISM
- Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial
- (2013) C. S. Kovacs et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia
- (2013) J. Rosenstock et al. DIABETES OBESITY & METABOLISM
- A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes
- (2013) E. Ferrannini et al. DIABETES OBESITY & METABOLISM
- Effect of food on the pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and assessment of dose proportionality in healthy volunteers
- (2013) Sreeraj Macha et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes
- (2013) Matthew M. Riggs et al. JOURNAL OF CLINICAL PHARMACOLOGY
- The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM)
- (2013) Jan N. Basile JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Urinary tract infections in patients with diabetes treated with dapagliflozin
- (2013) Kristina M. Johnsson et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin
- (2013) Kristina M. Johnsson et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- SGLT inhibitors in management of diabetes
- (2013) Abd A Tahrani et al. Lancet Diabetes & Endocrinology
- Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
- (2013) Michael Roden et al. Lancet Diabetes & Endocrinology
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus
- (2013) Tim Heise et al. Diabetes Therapy
- Pharmacokinetics of Empagliflozin, a Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor, Coadministered with Sitagliptin in Healthy Volunteers
- (2012) Tobias Brand et al. ADVANCES IN THERAPY
- Dendritic Cells Promote Macrophage Infiltration and Comprise a Substantial Proportion of Obesity-Associated Increases in CD11c+ Cells in Adipose Tissue and Liver
- (2012) M. Stefanovic-Racic et al. DIABETES
- Standards of Medical Care in Diabetes--2013
- (2012) DIABETES CARE
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2012) S. E. Inzucchi et al. DIABETES CARE
- Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers
- (2012) S. Macha et al. DIABETES OBESITY & METABOLISM
- Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers
- (2012) Sreeraj Macha et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Incidence of genital infection among patients with type 2 diabetes in the UK General Practice Research Database
- (2012) Ishan Hirji et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Incidence of urinary tract infection among patients with type 2 diabetes in the UK General Practice Research Database (GPRD)
- (2012) Ishan Hirji et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Proportion of patients at HbA1c target
- (2011) K. Esposito et al. DIABETES OBESITY & METABOLISM
- Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
- (2011) R. Grempler et al. DIABETES OBESITY & METABOLISM
- Patient adherence to medication requirements for therapy of type 2 diabetes
- (2011) C. J. Bailey et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Biology of Human Sodium Glucose Transporters
- (2011) Ernest M. Wright et al. PHYSIOLOGICAL REVIEWS
- SLC2A9 Is a High-Capacity Urate Transporter in Humans
- (2008) Mark J Caulfield et al. PLOS MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More